Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Abbott Laboratories current ratio improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Abbott Laboratories quick ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Abbott Laboratories cash ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
Current Ratio
Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Current assets | 23,429 | 24,239 | 23,492 | 22,627 | 21,817 | 20,441 | 17,390 | 17,221 | 15,498 | 15,667 | 16,119 | 15,195 | 14,409 | 14,632 | 18,196 | 14,122 | 14,964 | 20,147 | 21,377 | 19,983 | 19,329 | |||||||
Current liabilities | 12,647 | 13,105 | 12,867 | 12,614 | 12,462 | 11,907 | 10,257 | 10,959 | 10,808 | 10,863 | 10,491 | 9,062 | 9,113 | 9,012 | 12,776 | 8,951 | 9,010 | 8,912 | 7,935 | 6,803 | 6,646 | |||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Current ratio1 | 1.85 | 1.85 | 1.83 | 1.79 | 1.75 | 1.72 | 1.70 | 1.57 | 1.43 | 1.44 | 1.54 | 1.68 | 1.58 | 1.62 | 1.42 | 1.58 | 1.66 | 2.26 | 2.69 | 2.94 | 2.91 | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Current Ratio, Competitors2 | ||||||||||||||||||||||||||||
Anthem Inc. | 1.36 | 1.47 | 1.48 | 1.49 | 1.57 | 1.55 | 1.59 | 1.64 | 1.53 | 1.65 | 1.70 | 1.64 | 1.61 | 1.56 | 1.54 | 1.52 | 1.49 | 1.55 | 1.51 | 1.65 | 1.64 | |||||||
Bristol-Myers Squibb Co. | 1.32 | 1.52 | 1.47 | 1.54 | 1.56 | 1.58 | 1.67 | 1.47 | 1.66 | 1.60 | 3.83 | 3.88 | 1.93 | 1.61 | 1.53 | 1.40 | 1.52 | 1.55 | 1.59 | 1.59 | 1.60 | |||||||
CVS Health Corp. | 0.88 | 0.88 | 0.94 | 0.95 | 0.93 | 0.91 | 0.95 | 0.98 | 0.99 | 0.94 | 0.92 | 0.95 | 0.95 | 1.03 | 2.44 | 2.34 | 2.37 | 1.02 | 1.05 | 1.09 | 1.08 | |||||||
Danaher Corp. | 1.68 | 1.43 | 1.48 | 2.26 | 2.05 | 1.86 | 2.08 | 2.20 | 1.32 | 5.19 | 3.43 | 2.32 | 2.18 | 1.47 | 1.53 | 1.50 | 1.59 | 1.43 | 1.43 | 1.49 | 1.05 | |||||||
Intuitive Surgical Inc. | 5.22 | 5.08 | 5.58 | 5.99 | 6.71 | 6.86 | 7.04 | 6.38 | 4.96 | 4.53 | 4.64 | 5.04 | 5.44 | 5.28 | 6.05 | 5.98 | 5.82 | 3.99 | 4.76 | 4.41 | 3.88 | |||||||
Medtronic PLC | 2.89 | 2.65 | 2.10 | 2.16 | 1.87 | 2.13 | 2.75 | 2.77 | 2.67 | 2.59 | 2.36 | 2.56 | 2.46 | 2.28 | 2.43 | 2.40 | 1.64 | 1.75 | 1.77 | 2.35 | 2.98 | |||||||
UnitedHealth Group Inc. | 0.78 | 0.79 | 0.77 | 0.77 | 0.74 | 0.74 | 0.82 | 0.84 | 0.75 | 0.69 | 0.70 | 0.67 | 0.73 | 0.73 | 0.69 | 0.75 | 0.71 | 0.73 | 0.70 | 0.72 | 0.71 |
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Current ratio = Current assets ÷ Current liabilities
= 23,429 ÷ 12,647 = 1.85
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Abbott Laboratories current ratio improved from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Quick Ratio
Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Cash and cash equivalents | 7,675 | 9,799 | 9,302 | 8,658 | 8,054 | 6,838 | 4,480 | 4,763 | 3,377 | 3,860 | 4,091 | 3,137 | 3,022 | 3,844 | 7,369 | 3,065 | 3,857 | 9,407 | 11,012 | 9,675 | 8,706 | |||||||
Short-term investments | 483 | 450 | 390 | 286 | 318 | 310 | 251 | 274 | 291 | 280 | 244 | 239 | 239 | 242 | 181 | 199 | 185 | 203 | 187 | 160 | 154 | |||||||
Trade receivables, less allowances | 7,179 | 6,487 | 6,405 | 6,113 | 6,096 | 6,414 | 5,649 | 5,140 | 5,292 | 5,425 | 5,450 | 5,548 | 5,345 | 5,182 | 5,271 | 5,192 | 5,356 | 5,249 | 4,800 | 4,633 | 4,510 | |||||||
Total quick assets | 15,337 | 16,736 | 16,097 | 15,057 | 14,468 | 13,562 | 10,380 | 10,177 | 8,960 | 9,565 | 9,785 | 8,924 | 8,606 | 9,268 | 12,821 | 8,456 | 9,398 | 14,859 | 15,999 | 14,468 | 13,370 | |||||||
Current liabilities | 12,647 | 13,105 | 12,867 | 12,614 | 12,462 | 11,907 | 10,257 | 10,959 | 10,808 | 10,863 | 10,491 | 9,062 | 9,113 | 9,012 | 12,776 | 8,951 | 9,010 | 8,912 | 7,935 | 6,803 | 6,646 | |||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Quick ratio1 | 1.21 | 1.28 | 1.25 | 1.19 | 1.16 | 1.14 | 1.01 | 0.93 | 0.83 | 0.88 | 0.93 | 0.98 | 0.94 | 1.03 | 1.00 | 0.94 | 1.04 | 1.67 | 2.02 | 2.13 | 2.01 | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||
Anthem Inc. | 1.23 | 1.33 | 1.33 | 1.35 | 1.43 | 1.42 | 1.45 | 1.49 | 1.37 | 1.52 | 1.58 | 1.51 | 1.49 | 1.44 | 1.38 | 1.37 | 1.32 | 1.42 | 1.40 | 1.51 | 1.51 | |||||||
Bristol-Myers Squibb Co. | 1.03 | 1.20 | 1.16 | 1.16 | 1.25 | 1.28 | 1.43 | 1.26 | 1.38 | 1.26 | 3.63 | 3.61 | 1.64 | 1.39 | 1.31 | 1.18 | 1.29 | 1.37 | 1.38 | 1.36 | 1.37 | |||||||
CVS Health Corp. | 0.54 | 0.55 | 0.59 | 0.58 | 0.54 | 0.53 | 0.58 | 0.63 | 0.60 | 0.52 | 0.52 | 0.54 | 0.55 | 0.55 | 1.92 | 1.84 | 1.85 | 0.49 | 0.53 | 0.54 | 0.53 | |||||||
Danaher Corp. | 1.08 | 0.89 | 0.93 | 1.67 | 1.51 | 1.36 | 1.52 | 1.59 | 0.92 | 4.68 | 2.99 | 1.78 | 1.58 | 0.88 | 0.92 | 0.91 | 0.97 | 0.87 | 0.89 | 0.94 | 0.64 | |||||||
Intuitive Surgical Inc. | 4.40 | 4.34 | 4.66 | 5.12 | 5.76 | 5.96 | 5.93 | 5.40 | 4.00 | 3.75 | 3.80 | 4.15 | 4.53 | 4.56 | 5.28 | 5.20 | 5.15 | 3.51 | 4.25 | 3.84 | 3.36 | |||||||
Medtronic PLC | 2.06 | 1.91 | 1.58 | 1.63 | 1.37 | 1.50 | 2.05 | 2.02 | 1.95 | 1.90 | 1.69 | 1.88 | 1.83 | 1.71 | 1.85 | 1.84 | 1.25 | 1.36 | 1.33 | 1.76 | 2.30 | |||||||
UnitedHealth Group Inc. | 0.72 | 0.72 | 0.71 | 0.71 | 0.68 | 0.68 | 0.75 | 0.76 | 0.66 | 0.63 | 0.64 | 0.62 | 0.66 | 0.67 | 0.62 | 0.68 | 0.64 | 0.68 | 0.66 | 0.68 | 0.67 |
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 15,337 ÷ 12,647 = 1.21
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Abbott Laboratories quick ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
Cash Ratio
Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Cash and cash equivalents | 7,675 | 9,799 | 9,302 | 8,658 | 8,054 | 6,838 | 4,480 | 4,763 | 3,377 | 3,860 | 4,091 | 3,137 | 3,022 | 3,844 | 7,369 | 3,065 | 3,857 | 9,407 | 11,012 | 9,675 | 8,706 | |||||||
Short-term investments | 483 | 450 | 390 | 286 | 318 | 310 | 251 | 274 | 291 | 280 | 244 | 239 | 239 | 242 | 181 | 199 | 185 | 203 | 187 | 160 | 154 | |||||||
Total cash assets | 8,158 | 10,249 | 9,692 | 8,944 | 8,372 | 7,148 | 4,731 | 5,037 | 3,668 | 4,140 | 4,335 | 3,376 | 3,261 | 4,086 | 7,550 | 3,264 | 4,042 | 9,610 | 11,199 | 9,835 | 8,860 | |||||||
Current liabilities | 12,647 | 13,105 | 12,867 | 12,614 | 12,462 | 11,907 | 10,257 | 10,959 | 10,808 | 10,863 | 10,491 | 9,062 | 9,113 | 9,012 | 12,776 | 8,951 | 9,010 | 8,912 | 7,935 | 6,803 | 6,646 | |||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Cash ratio1 | 0.65 | 0.78 | 0.75 | 0.71 | 0.67 | 0.60 | 0.46 | 0.46 | 0.34 | 0.38 | 0.41 | 0.37 | 0.36 | 0.45 | 0.59 | 0.36 | 0.45 | 1.08 | 1.41 | 1.45 | 1.33 | |||||||
Benchmarks | ||||||||||||||||||||||||||||
Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||
Anthem Inc. | 0.86 | 0.95 | 0.97 | 0.97 | 1.08 | 1.04 | 1.04 | 1.10 | 0.95 | 1.08 | 1.14 | 1.07 | 1.04 | 1.01 | 0.99 | 0.99 | 0.97 | 1.05 | 1.08 | 1.12 | 1.15 | |||||||
Bristol-Myers Squibb Co. | 0.66 | 0.78 | 0.73 | 0.68 | 0.75 | 0.83 | 1.03 | 0.92 | 0.95 | 0.84 | 3.10 | 3.02 | 0.99 | 0.83 | 0.70 | 0.62 | 0.70 | 0.71 | 0.75 | 0.72 | 0.72 | |||||||
CVS Health Corp. | 0.16 | 0.18 | 0.20 | 0.17 | 0.15 | 0.18 | 0.19 | 0.27 | 0.21 | 0.15 | 0.14 | 0.17 | 0.16 | 0.15 | 1.42 | 1.39 | 1.39 | 0.06 | 0.09 | 0.08 | 0.08 | |||||||
Danaher Corp. | 0.49 | 0.32 | 0.35 | 1.07 | 0.93 | 0.82 | 0.94 | 0.99 | 0.52 | 4.04 | 2.40 | 1.08 | 0.84 | 0.16 | 0.17 | 0.20 | 0.24 | 0.13 | 0.15 | 0.17 | 0.13 | |||||||
Intuitive Surgical Inc. | 3.58 | 3.66 | 3.98 | 4.42 | 5.04 | 5.30 | 5.27 | 4.85 | 3.44 | 3.13 | 3.11 | 3.37 | 3.79 | 3.73 | 4.46 | 4.40 | 4.33 | 2.78 | 3.49 | 3.04 | 2.62 | |||||||
Medtronic PLC | 1.36 | 1.27 | 1.17 | 1.18 | 0.99 | 1.06 | 1.33 | 1.27 | 1.25 | 1.16 | 1.03 | 1.20 | 1.21 | 1.11 | 1.32 | 1.29 | 0.86 | 0.96 | 0.90 | 1.17 | 1.62 | |||||||
UnitedHealth Group Inc. | 0.37 | 0.36 | 0.35 | 0.35 | 0.33 | 0.33 | 0.37 | 0.42 | 0.35 | 0.28 | 0.30 | 0.32 | 0.32 | 0.33 | 0.30 | 0.40 | 0.37 | 0.37 | 0.39 | 0.37 | 0.39 |
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 8,158 ÷ 12,647 = 0.65
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Abbott Laboratories cash ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |